The Body PRO Covers: The XIV International AIDS Conference

Patterns of Resistance After Initial Regimen Failure

July 9, 2002

  • Resistance Profiles at Baseline and Following Virologic Failure for Subjects Randomized to Receive Abacavir (ABC)/Efavirenz (EFV)/Didanosine (ddI) +/-; Hydroxyurea (HU) After Failing Initial NRTI +/- PI Therapy (TuPeB4587)
    Authored by E.R. Lanier, Q. Liao, C. Cohen, S. Swindells, D. Berger, K. Tashima, B. Pobiner, S. Griffith, J. Hernandez
    View the original abstract

It is important to understand what types of viral resistance develop after a regimen fails. Although we have been looking at resistance to nucleoside analogues for some 12 years, the complexity is astounding and we still have a lot to learn. The more complex the combination, the more we may learn about how the virus escapes our therapies.

NZTA 4008 was a trial of rescue therapy for patients failing their first regimen of zidovudine (ZDV), epivir (3TC) and one or two protease inhibitors (PIs). Patients were randomized to receive abacavir (Ziagen), efavirenz (Sustiva) and ddI (Videx) with or without hydroxyurea. The main trial results were presented earlier, and showed that hydroxyurea had a minimal benefit in lowering viral load, but at a cost of higher toxicity and lower CD4 count responses. This paper looked at the pattern of resistance mutations in those patients breaking through.

One might expect to see resistance to efavirenz, early resistance to abacavir (such as M184V), broad resistance to abacavir (multiple TAMs -- thymidine analogue mutations, a.k.a. NAM or NEMS), or resistance to ddI. Perhaps the biggest risk might be that broad multi-drug resistance might emerge.

At study entry, 90 percent of patients had mutations conferring resistance to PIs. Seventy-six percent had both PI mutations and some mutations associated with nucleoside resistance. Those who had the v mutation and at least three TAMs had a much higher failure rate. The presence of M184V alone did not change the response rate.

The majority of patients acquired new mutations when they failed. The majority (8/10) acquired new resistance to NNRTIs such as efavirenz. The most common mutation was the K103N mutation, which leads to resistance to the whole class of NNRTIs. Six to ten developed the L74V mutation which leads to ddI resistance.

This study is interesting for several reasons. First, it confirms that abacavir remains useful in patients with the M184V mutation and one or two TAMs, but looses effect when there are three or more TAMs. Secondly, it showed that both ddI and NNRTI mutations contributed to treatment failure. Third, it showed that hydroxyurea did not change the pattern of resistance. Lastly, it showed the deep hole that a patient can be left in if they develop resistance to all three classes of available agents.

Previous | Next Session

Tell us what you think of The Body's conference coverage!

This article was provided by TheBodyPRO. It is a part of the publication The XIV International AIDS Conference.

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.